These new trials have shown great results.
Gizmodo:
On Wednesday, the companies disclosed the primary findings of a Phase 3 trial that tested their mRNA-based vaccine, which is designed to prevent people’s melanoma from returning. People who received the vaccine in combination with immunotherapy lived significantly longer without cancer recurrence than those who only received immunotherapy, the trial reportedly showed. If approved, this vaccine could herald an important new approach to keeping cancers at bay.
“These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality,” said Stéphane Bancel, CEO of Moderna, in a statement released by the companies.
Open thread.
